Subcutaneous bortezomib might be standard of care for patients with multiple myeloma: a systematic review and meta-analysis

Z Ye, J Chen, Z Xuan, W Yang… - Drug Design, Development …, 2019 - Taylor & Francis
Background: Administration of subcutaneous (SC) bortezomib in patients with multiple
myeloma (MM) has increased in recent years. Yet, it is unclear whether there is sufficient …
被引用次数：14 相关文章
[PDF] scienceopen.com

[PDF][PDF] Subcutaneous bortezomib might be standard of care for patients with multiple myeloma: a systematic review and meta-analysis

Z Ye, J Chen, Z Xuan, W Yang… - … Design, Development and …, 2019 - scienceopen.com
Background: Administration of subcutaneous (SC) bortezomib in patients with multiple
myeloma (MM) has increased in recent years. Yet, it is unclear whether there is sufficient …

Subcutaneous bortezomib might be standard of care for patients with multiple myeloma: a systematic review and meta-analysis.

Z Ye, J Chen, Z Xuan, W Yang - Drug Design, Development and …, 2019 - europepmc.org
Background: Administration of subcutaneous (SC) bortezomib in patients with multiple
myeloma (MM) has increased in recent years. Yet, it is unclear whether there is sufficient …

Subcutaneous bortezomib might be standard of care for patients with multiple myeloma: a systematic review and meta-analysis

Z Ye, J Chen, Z Xuan, W Yang… - Drug Design, Development …, 2019 - dovepress.com
Background: Administration of subcutaneous (SC) bortezomib in patients with multiple
myeloma (MM) has increased in recent years. Yet, it is unclear whether there is sufficient …
[HTML] nih.gov

[HTML][HTML] Subcutaneous bortezomib might be standard of care for patients with multiple myeloma: a systematic review and meta-analysis

Z Ye, J Chen, Z Xuan, W Yang… - Drug Design, Development …, 2019 - ncbi.nlm.nih.gov
Background: Administration of subcutaneous (SC) bortezomib in patients with multiple
myeloma (MM) has increased in recent years. Yet, it is unclear whether there is sufficient …

Subcutaneous bortezomib might be standard of care for patients with multiple myeloma: a systematic review and meta-analysis.

Z Ye, J Chen, Z Xuan, W Yang, J Chen - Drug Design, Development …, 2019 - go.gale.com
Multiple myeloma (MM) is characterized by the neoplastic proliferation of plasma cells
producing a monoclonal immunoglobulin. MM accounts for approximately 1-2% of all …

Subcutaneous bortezomib might be standard of care for patients with multiple myeloma: a systematic review and meta-analysis

Z Ye, J Chen, Z Xuan, W Yang… - Drug design …, 2019 - pubmed.ncbi.nlm.nih.gov
Background: Administration of subcutaneous (SC) bortezomib in patients with multiple
myeloma (MM) has increased in recent years. Yet, it is unclear whether there is sufficient …
[PDF] semanticscholar.org

[PDF][PDF] Subcutaneous bortezomib might be standard of care for patients with multiple myeloma: a systematic review and meta-analysis

Z Ye, J Chen, Z Xuan, W Yang… - Drug Design …, 2019 - pdfs.semanticscholar.org
Background: Administration of subcutaneous (SC) bortezomib in patients with multiple
myeloma (MM) has increased in recent years. Yet, it is unclear whether there is sufficient …

Subcutaneous bortezomib might be standard of care for patients with multiple myeloma: a systematic review and meta-analysis

Z Ye, J Chen, Z Xuan, W Yang… - Drug Design …, 2019 - search.proquest.com
Background: Administration of subcutaneous (SC) bortezomib in patients with multiple
myeloma (MM) has increased in recent years. Yet, it is unclear whether there is sufficient …

Subcutaneous bortezomib might be standard of care for patients with multiple myeloma: a systematic review and meta-analysis.

Z Ye, J Chen, Z Xuan, W Yang - Drug Design, Development and …, 2019 - europepmc.org
Background: Administration of subcutaneous (SC) bortezomib in patients with multiple
myeloma (MM) has increased in recent years. Yet, it is unclear whether there is sufficient …